In April ----, the Australian Productivity Commission published a report arguing that pharmaceutical firms are boosting revenues by extending patents in the country, slowing access to cheaper drugs. The commission also warned of pay for delay practices in Australia and has called for an investigation into the practice. In May ----, the incumbent Liberal-National coalition announced that it will invest AUD-mn towards improving the clinical trial landscape in Australia. In particular, the coalition intends to make it easier for clinical trial businesses to operate and provide the necessary administrative support to expedite trial commencement. In July ----, local news sources reported that a global supply shortage of Bexsero (meningococcal group B vaccine) has hit Australia. ...In July ----, local news sources reported that a global supply shortage of Bexsero (meningococcal group B vaccine) has hit Australia. GlaxoSmithKline, the firm producing the vaccine notes that the shortage will be for the next few months.
...Other markets such as India and China competing as viable alternatives for cost- effective biotechnology research & development for companies. A failure to revise pricing regulations, in particular with regards to introducing price rises, deterring multinational investment. ...The FTA opening up the market to competition from low-cost US-made generic drugs. Proposed legislation by the Therapeutic Goods Administration to raise the number of clinical trials post-approval to make the industry a more challenging proposition. Higher scrutiny of pharmaceutical advertising practices and industry self-regulation code. ...Proposed legislation by the Therapeutic Goods Administration to raise the number of clinical trials post-approval to make the industry a more challenging proposition. Higher scrutiny of pharmaceutical advertising practices and industry self-regulation code.
...Australia s Liberal-National coalition formed the government for a second term following the July - federal elections but we believe that it will not be able to significantly improve the country s business environment and economic growth prospects over the coming years. The coalition s expected lack of majority in the Senate suggests that risks of policies being delayed and diluted are high. ...